Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246
Study sponsor: SIGA Technologies
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2010-01Actual
Enrollment · participants107Actual
Source updated2026-09-11Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.